Rishi Razdan, MD, Medical Director of Azura Vascular Care Jacksonville in Jacksonville, Florida, presented mid-term results from the Venova Medical sponsored VENOS-2 study during the 2025 Controversies in Dialysis Access (CiDA) meeting held in Boston, Massachusetts. The VENOS-2 study (NCT06712251) is investigating the safety and efficacy of the Velocity® pAVF System when used to create a percutaneous arteriovenous (AV) fistula for hemodialysis access in patients with advanced or end stage kidney disease. This multicenter, single-arm study has enrolled 23 subjects at 5 sites in the U.S.
Dr. Razden reported that 87% of subjects have achieved unassisted physiologic fistula maturation to date after an early and robust increase in access flow within the intended cannulation zone with a mean time to initial cannulation of 63 days. He noted that the percutaneous AVF feels and functions similar to a surgical AVF, simplifying initial cannulation. He concluded that Velocity pAVF is a simple method for creating functional hemodialysis access with demonstrated reproducibility of successful implant placement and consistent and positive flow dynamics across all study sites.
